- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01006577
Side-to-end Anastomosis Versus Colon J Pouch for Reconstruction After Low Anterior Resection for Rectal Cancer (SAVE) (SAVE)
Primary hypothesis: Side-to-end anastomosis is non-inferior to colon J pouch for reconstruction after low anterior resection for rectal cancer in fecal incontinence (Wexner score).
Research questions: Are there differences between side-to-end anastomosis and colon J pouch in
- bowel function (fecal incontinence, frequency of bowel movements, rectal urgency, incomplete evacuation)
- quality of life
- sexual function
- urinary function
- postoperative complications
- operation time/ institutional costs
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Experimental intervention: Low anterior resection for rectal cancer < 12 cm from the anal verge with total mesorectal excision (TME), ligation of the inferior mesenteric artery close to the aorta, mobilization of the splenic flexure, radical lymph node dissection and side-to-end colorectal/ coloanal anastomosis (STE). The blind end of the descending colon (3-5 cm long) is closed with a linear stapler. Stapling of the anastomosis is done by introducing the stapler from the anus by the assistant surgeon while the surgeon is holding the descending colon in the correct position. The anastomosis is performed on the antimesenteric aspect of the descending colon. The length of the blind end is measured and the integrity of the anastomosis is tested intraoperatively. The intended minimal distal clearance margin from the tumor is 2 cm. A protective loop ileostomy will be performed regularly which is intended to be closed 3 months postoperatively.
Control intervention: Low anterior resection for rectal cancer with total mesorectal excision (TME), ligation of the inferior mesenteric artery close to the aorta, mobilization of the splenic flexure, radical lymph node dissection and colon J pouch rectal/colon J pouch anal anastomosis (CJP). The colon J Pouch is formed by the descending colon by stapling with a defined pouch limb length of 5-6 cm, which is measured intraoperatively. The stapling is done by introducing the stapler from the anus by the assistant surgeon while the surgeon is holding the descending colon in the correct position. The integrity of the anastomosis is tested intraoperatively. The intended minimal distal clearance margin from the tumor is 2 cm. A protective loop ileostomy will be performed regularly which is intended to be closed 3 months postoperatively.
Follow-up per patient: 24 months postoperatively
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Johannes C Lauscher, MD
- Phone Number: 0049 30 8445 2543
- Email: johannes.lauscher@charite.de
Study Contact Backup
- Name: Jörg-Peter Ritz, PD Dr.
- Phone Number: 0049 30 8445 2503
- Email: joerg-peter.ritz@charite.de
Study Locations
-
-
-
Berlin, Germany, D-12200
- Charité Campus Benjamin Franklin; Hindenburgdamm 30
-
Contact:
- Johannes C Lauscher, MD
- Phone Number: 0049 30 8445 2543
- Email: johannes.lauscher@charite.de
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- patients with histological proven middle to low rectal cancer (< 12 cm from the anal verge) requiring low anterior resection with TME
- with or without (neo)-adjuvant radiochemotherapy
- age ≥18 years
- normal preoperative sphincter status (Wexner score = 0)
Exclusion Criteria:
- synchronous metastasis
- age > 80 years
- previous colon resection
- inflammatory bowel disease
- previous pelvic malignant tumor
- no anterior resection/ TME possible
- synchronous other malignant disease
- emergency operation
- local excision by colonoscopy possible
- unability to complete or comprehend the preoperative questionnaire
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: colon j pouch
Control intervention: Low anterior resection for rectal cancer with total mesorectal excision (TME), ligation of the inferior mesenteric artery, mobilization of the splenic flexure, radical lymph node dissection and colon J pouch rectal/colon J pouch anal anastomosis (CJP).
The colon J Pouch is formed by the descending colon by stapling.
The intended minimal distal clearance margin from the tumor is 2 cm.
A protective loop ileostomy will be performed regularly which is intended to be closed 3 months postoperatively.
|
Low anterior resection for rectal cancer with total mesorectal excision (TME), ligation of the inferior mesenteric artery close to the aorta, mobilization of the splenic flexure, radical lymph node dissection and colon J pouch rectal/colon J pouch anal anastomosis (CJP).
The colon J Pouch is formed by the descending colon by stapling with a defined pouch limb length of 5-6 cm, which is measured intraoperatively.
The stapling is done by introducing the stapler from the anus by the assistant surgeon while the surgeon is holding the descending colon in the correct position.
The integrity of the anastomosis is tested intraoperatively.
The intended minimal distal clearance margin from the tumor is 2 cm.
A protective loop ileostomy will be performed regularly which is intended to be closed 3 months postoperatively.
|
Experimental: side-to-end anastomosis (STE)
Experimental intervention: Low anterior resection for rectal cancer < 12 cm from the anal verge with total mesorectal excision (TME), ligation of the inferior mesenteric artery, mobilization of the splenic flexure, radical lymph node dissection and side-to-end colorectal/ coloanal anastomosis (STE).
The blind end of the descending colon is closed with a linear stapler.
The length of the blind end is measured and the integrity of the anastomosis is tested intraoperatively.
The intended minimal distal clearance margin from the tumor is 2 cm.
A protective loop ileostomy will be performed regularly which is intended to be closed 3 months postoperatively.
|
Low anterior resection for rectal cancer < 12 cm from the anal verge with total mesorectal excision (TME), ligation of the inferior mesenteric artery close to the aorta, mobilization of the splenic flexure, radical lymph node dissection and side-to-end colorectal/ coloanal anastomosis (STE).
The blind end of the descending colon (3-5 cm long) is closed with a linear stapler.
Stapling of the anastomosis is done by introducing the stapler from the anus by the assistant surgeon while the surgeon is holding the descending colon in the correct position.
The anastomosis is performed on the antimesenteric aspect of the descending colon.
The length of the blind end is measured and the integrity of the anastomosis is tested intraoperatively.
The intended minimal distal clearance margin from the tumor is 2 cm.
A protective loop ileostomy will be performed regularly which is intended to be closed 3 months postoperatively.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Side-to-end anastomosis is not inferior not colon J pouch in terms of fecal incontinence. fecal incontinence (Wexner score)
Time Frame: First patient in to last patient out: 03/2010 -03/2015
|
First patient in to last patient out: 03/2010 -03/2015
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
anorectal function
Time Frame: 03/2010-03/2015
|
03/2010-03/2015
|
quality of life
Time Frame: 03/2010-03/2015
|
03/2010-03/2015
|
postoperative complications
Time Frame: 03/2010-03/2015
|
03/2010-03/2015
|
sexual function
Time Frame: 03/2010-03/2015
|
03/2010-03/2015
|
urinary function
Time Frame: 03/2010-03/2015
|
03/2010-03/2015
|
operation time
Time Frame: 03/2010-03/2015
|
03/2010-03/2015
|
institutional costs
Time Frame: 03/2010-03/2015
|
03/2010-03/2015
|
local recurrence
Time Frame: 03/2010-03/2015
|
03/2010-03/2015
|
cancer related deaths
Time Frame: 03/2010-03/2015
|
03/2010-03/2015
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Johannes C Lauscher, MD, Charité Campus Benjamin Franklin; Department of General, Vascular and Thoracic Surgery
- Principal Investigator: Jörg-Peter Ritz, PD Dr., Charité Campus Benjamin Franklin; Department of General, Vascular and Thoracic Surgery
- Study Chair: Heinz J Buhr, Prof. Dr., Charité Campus Benjamin Franklin; Department of General, Vascular and Thoracic Surgery
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
- quality of life
- rectal cancer
- postoperative complications
- fecal incontinence
- side-to-end anastomosis
- colon J pouch
- anorectal function
- Are there differences between side-to-end anastomosis and colon J pouch in
- bowel function (fecal incontinence, frequency of bowel movements, rectal urgency, incomplete evacuation)
- operation time/ institutional costs
Additional Relevant MeSH Terms
Other Study ID Numbers
- EA4/105/08
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Rectal Cancer
-
Ohio State University Comprehensive Cancer CenterNovartis Pharmaceuticals; National Comprehensive Cancer NetworkCompletedStage IIA Rectal Cancer | Stage IIB Rectal Cancer | Stage IIC Rectal Cancer | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Recurrent Rectal CancerUnited States
-
M.D. Anderson Cancer CenterRecruitingEvaluation of Quality of Life and Utilities Following Surgical Treatment of Stage I-IV Rectal CancerStage III Rectal Cancer AJCC v8 | Stage IIIA Rectal Cancer AJCC v8 | Stage IIIB Rectal Cancer AJCC v8 | Stage IIIC Rectal Cancer AJCC v8 | Stage IV Rectal Cancer AJCC v8 | Stage IVA Rectal Cancer AJCC v8 | Stage IVB Rectal Cancer AJCC v8 | Stage IVC Rectal Cancer AJCC v8 | Rectal Adenocarcinoma | Stage... and other conditionsUnited States
-
OHSU Knight Cancer InstituteNatera, Inc.RecruitingEstablishing a ctDNA Biomarker to Improve Organ Preserving Strategies in Patients With Rectal CancerStage III Rectal Cancer AJCC v8 | Stage IIIA Rectal Cancer AJCC v8 | Stage IIIB Rectal Cancer AJCC v8 | Stage IIIC Rectal Cancer AJCC v8 | Rectal Adenocarcinoma | Stage IIA Rectal Cancer AJCC v8 | Stage IIB Rectal Cancer AJCC v8 | Stage II Rectal Cancer AJCC v8 | Stage IIC Rectal Cancer AJCC v8United States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingStage III Rectal Cancer AJCC v8 | Stage IIIA Rectal Cancer AJCC v8 | Stage IIIB Rectal Cancer AJCC v8 | Stage IIIC Rectal Cancer AJCC v8 | Rectal Adenocarcinoma | Stage IIA Rectal Cancer AJCC v8 | Stage IIB Rectal Cancer AJCC v8 | Stage II Rectal Cancer AJCC v8 | Stage IIC Rectal Cancer AJCC v8United States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)WithdrawnStage IIA Rectal Cancer | Stage IIB Rectal Cancer | Stage IIC Rectal Cancer | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Rectal AdenocarcinomaUnited States
-
OHSU Knight Cancer InstituteOregon Health and Science University; Taiho Pharmaceutical Co., Ltd.RecruitingStage III Rectal Cancer AJCC v8 | Stage IIIA Rectal Cancer AJCC v8 | Stage IIIB Rectal Cancer AJCC v8 | Stage IIIC Rectal Cancer AJCC v8 | Rectal Adenocarcinoma | Stage IIA Rectal Cancer AJCC v8 | Stage IIB Rectal Cancer AJCC v8United States
-
Jonsson Comprehensive Cancer CenterNatera, Inc.; The Joseph Drown FoundationRecruitingStage III Rectal Cancer AJCC v8 | Stage IIIA Rectal Cancer AJCC v8 | Stage IIIB Rectal Cancer AJCC v8 | Stage IIIC Rectal Cancer AJCC v8 | Rectal Adenocarcinoma | Stage IIA Rectal Cancer AJCC v8 | Stage IIB Rectal Cancer AJCC v8 | Stage II Rectal Cancer AJCC v8 | Stage IIC Rectal Cancer AJCC v8 | Locally...United States
-
Case Comprehensive Cancer CenterCompletedStage IIA Rectal Cancer | Stage IIB Rectal Cancer | Stage IIC Rectal Cancer | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Recurrent Colon Cancer | Recurrent Rectal Cancer | Stage IVA Colon Cancer | Stage IVA Rectal Cancer and other conditionsUnited States
-
National Cancer Institute (NCI)Active, not recruitingMetastatic Rectal Adenocarcinoma | Rectal Adenocarcinoma | Stage III Rectal Cancer AJCC v7 | Stage IIIA Rectal Cancer AJCC v7 | Stage IIIB Rectal Cancer AJCC v7 | Stage IIIC Rectal Cancer AJCC v7 | Stage IV Rectal Cancer AJCC v7 | Stage IVA Rectal Cancer AJCC v7 | Stage IVB Rectal Cancer AJCC v7 | Locally...United States
-
City of Hope Medical CenterWithdrawnRecurrent Rectal Cancer | Stage I Rectal Cancer | Stage II Rectal Cancer | Stage III Rectal Cancer
Clinical Trials on colon j pouch
-
The Cleveland ClinicCompletedRectal CancerUnited States
-
Swiss Group for Clinical Cancer ResearchCompletedColorectal CancerSwitzerland, Germany
-
Academisch Medisch Centrum - Universiteit van Amsterdam...Dutch Digestive Diseases Foundation; Commission of Applied Clinical Research...Completed
-
RAI Services CompanyCompletedSmoking | Tobacco Use | Tobacco SmokingUnited States
-
Radboud University Medical CenterCanisius-Wilhelmina Hospital; Johnson & Johnson Medical BV, The NetherlandsCompletedArthroplasty, Replacement, KneeNetherlands
-
International AIDS Vaccine InitiativeBrigham and Women's Hospital; Fred Hutchinson Cancer Center; Rockefeller UniversityActive, not recruitingHIV-1-infectionUnited States, Uganda, Kenya, Rwanda, South Africa
-
ConvaTec Inc.Completed
-
University of AlbertaSernova CorpTerminated
-
Kantonsspital LiestalRecruiting